Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.62 and traded as high as $12.87. Dynavax Technologies shares last traded at $12.62, with a volume of 5,449,688 shares.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a "buy" rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.
Read Our Latest Analysis on Dynavax Technologies
Dynavax Technologies Stock Performance
The stock has a fifty day simple moving average of $12.72 and a two-hundred day simple moving average of $11.62. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 97.16 and a beta of 1.34.
Institutional Investors Weigh In On Dynavax Technologies
A number of hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 1,457 shares during the period. Sanctuary Advisors LLC grew its holdings in Dynavax Technologies by 9.1% in the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company's stock worth $197,000 after purchasing an additional 1,484 shares during the period. Nisa Investment Advisors LLC increased its stake in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 1,679 shares in the last quarter. US Bancorp DE raised its holdings in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,034 shares during the period. Finally, Parkman Healthcare Partners LLC boosted its position in shares of Dynavax Technologies by 1.2% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company's stock worth $2,445,000 after purchasing an additional 2,629 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.
About Dynavax Technologies
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Read More
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
